GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (NAS:YMTX) » Definitions » PB Ratio

Yumanity Therapeutics (Yumanity Therapeutics) PB Ratio : 3.75 (As of May. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-06), Yumanity Therapeutics's share price is $1.89. Yumanity Therapeutics's Book Value per Share for the quarter that ended in Sep. 2022 was $0.50. Hence, Yumanity Therapeutics's PB Ratio of today is 3.75.

The historical rank and industry rank for Yumanity Therapeutics's PB Ratio or its related term are showing as below:

YMTX's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.505
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Yumanity Therapeutics PB Ratio Historical Data

The historical data trend for Yumanity Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics PB Ratio Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
PB Ratio
- 3.08 1.34

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.28 1.34 1.39 2.49 3.12

Competitive Comparison of Yumanity Therapeutics's PB Ratio

For the Biotechnology subindustry, Yumanity Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yumanity Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yumanity Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Yumanity Therapeutics's PB Ratio falls into.



Yumanity Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Yumanity Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2022)
=1.89/0.504
=3.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Yumanity Therapeutics  (NAS:YMTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Yumanity Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (Yumanity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.
Executives
Shawn Iadonato director, officer: Chief Executive Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips officer: President C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Raymond J. Bartoszek director C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker officer: Chief Financial Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny officer: General Counsel C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux officer: Chief Scientific Officer C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Richard Peters director, officer: President & CEO MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Devin Whittemore Smith officer: SVP and General Counsel C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Marie Epstein officer: Principal Accounting Officer C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Michael D Wyzga officer: See Remarks C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Paulash Mohsen officer: Chief Business Officer C/O YUMANITY THERAPEUTICS, INC., 40 GUESS STREET SUITE 4410, BOSTON MA 02135
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma officer: EVP, Head of R&D C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
N Anthony Coles director, officer: Executive Chair MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054